blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2357184

EP2357184 - Imidazoquinoxaline compounds as immunomodulators [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  01.01.2016
Database last updated on 13.07.2024
Most recent event   Tooltip08.12.2017Lapse of the patent in a contracting state
New state(s): LU		published on 10.01.2018  [2018/02]
Applicant(s)For all designated states
Novartis AG
Lichtstrasse 35
4056 Basel / CH
[2011/33]
Inventor(s)01 / Sutton, James
Novartis Vaccines and Diagnostics, Inc.
P.O. Box 8097
Emeryville, CA 94662-8097 / US
02 / Xu, Feng
Novartis Vaccines and Diagnostics, Inc.
P.O. Box 8097
Emeryville, CA 94662-8097 / US
03 / Valiante, Nicholas
Novartis Vaccines and Diagnostics, Inc.
P.O. Box 8097
Emeryville, CA 94662-8097 / US
04 / Lan, Jiong
Novartis Vaccines and Diagnostics, Inc.
P.O. Box 8097
Emeryville, CA 94662-8097 / US
 [2015/09]
Former [2011/33]01 / Sutton, James
Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097
Emeryville, CA 94662-8097 / US
02 / Xu, Feng
Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097
Emeryville, CA 94662-8097 / US
03 / Valiante, Nicholas
Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097
Emeryville, CA 94662-8097 / US
04 / Lan, Jiong
Novartis Vaccines and Diagnostics, Inc. P.O. Box 8097
Emeryville, CA 94662-8097 / US
Representative(s)Warner, James Alexander
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2015/09]
Former [2011/33]Warner, James Alexander
Carpmaels & Ransford One Southampton Row London
WC1B 5HA / GB
Application number, filing date11164995.023.03.2007
[2011/33]
Priority number, dateUS20060785545P23.03.2006         Original published format: US 785545 P
[2011/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2357184
Date:17.08.2011
Language:EN
[2011/33]
Type: B1 Patent specification 
No.:EP2357184
Date:25.02.2015
Language:EN
[2015/09]
Search report(s)(Supplementary) European search report - dispatched on:EP15.07.2011
ClassificationIPC:C07D487/04, C07H7/06, A61K31/4985, A61P37/00
[2011/33]
CPC:
C07D487/04 (EP,US); A61K31/4985 (US); A61K39/21 (US);
A61K39/39 (US); A61P37/00 (EP); A61P37/04 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2011/33]
TitleGerman:Imidazochinoxalinverbindungen als Immunmodulatoren[2011/33]
English:Imidazoquinoxaline compounds as immunomodulators[2011/33]
French:Composés d'imidazoquinoxaline en tant qu'immunomodulateurs[2011/33]
Examination procedure17.02.2012Amendment by applicant (claims and/or description)
17.02.2012Examination requested  [2012/18]
04.05.2012Despatch of a communication from the examining division (Time limit: M06)
14.11.2012Reply to a communication from the examining division
19.09.2013Despatch of a communication from the examining division (Time limit: M06)
31.03.2014Reply to a communication from the examining division
25.04.2014Communication of intention to grant the patent
16.10.2014Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
19.12.2014Fee for grant paid
19.12.2014Fee for publishing/printing paid
19.12.2014Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP07759315.0  / EP2010537
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20070759315) is  04.05.2009
Opposition(s)26.11.2015No opposition filed within time limit [2016/05]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
19.12.2014Request for further processing filed
19.12.2014Full payment received (date of receipt of payment)
Request granted
26.01.2015Decision despatched
Fees paidRenewal fee
05.05.2011Renewal fee patent year 03
05.05.2011Renewal fee patent year 04
05.05.2011Renewal fee patent year 05
14.03.2012Renewal fee patent year 06
11.03.2013Renewal fee patent year 07
13.03.2014Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU23.03.2007
AT25.02.2015
BE25.02.2015
BG25.02.2015
CY25.02.2015
CZ25.02.2015
DK25.02.2015
EE25.02.2015
FI25.02.2015
IT25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
MT25.02.2015
NL25.02.2015
PL25.02.2015
RO25.02.2015
SE25.02.2015
SI25.02.2015
SK25.02.2015
TR25.02.2015
IE23.03.2015
LU23.03.2015
CH31.03.2015
LI31.03.2015
GR26.05.2015
IS25.06.2015
PT25.06.2015
[2018/02]
Former [2017/39]HU23.03.2007
AT25.02.2015
BE25.02.2015
BG25.02.2015
CY25.02.2015
CZ25.02.2015
DK25.02.2015
EE25.02.2015
FI25.02.2015
IT25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
MT25.02.2015
NL25.02.2015
PL25.02.2015
RO25.02.2015
SE25.02.2015
SI25.02.2015
SK25.02.2015
TR25.02.2015
IE23.03.2015
CH31.03.2015
LI31.03.2015
GR26.05.2015
IS25.06.2015
PT25.06.2015
Former [2017/03]AT25.02.2015
BE25.02.2015
CZ25.02.2015
DK25.02.2015
EE25.02.2015
FI25.02.2015
IT25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
MT25.02.2015
NL25.02.2015
PL25.02.2015
RO25.02.2015
SE25.02.2015
SI25.02.2015
SK25.02.2015
IE23.03.2015
CH31.03.2015
LI31.03.2015
GR26.05.2015
IS25.06.2015
Former [2016/24]AT25.02.2015
BE25.02.2015
CZ25.02.2015
DK25.02.2015
EE25.02.2015
FI25.02.2015
IT25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
NL25.02.2015
PL25.02.2015
RO25.02.2015
SE25.02.2015
SI25.02.2015
SK25.02.2015
IE23.03.2015
CH31.03.2015
LI31.03.2015
GR26.05.2015
IS25.06.2015
Former [2016/12]AT25.02.2015
CZ25.02.2015
DK25.02.2015
EE25.02.2015
FI25.02.2015
IT25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
NL25.02.2015
PL25.02.2015
RO25.02.2015
SE25.02.2015
SI25.02.2015
SK25.02.2015
IE23.03.2015
CH31.03.2015
LI31.03.2015
GR26.05.2015
IS25.06.2015
Former [2016/07]AT25.02.2015
CZ25.02.2015
DK25.02.2015
EE25.02.2015
FI25.02.2015
IT25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
NL25.02.2015
PL25.02.2015
RO25.02.2015
SE25.02.2015
SK25.02.2015
IE23.03.2015
CH31.03.2015
LI31.03.2015
GR26.05.2015
IS25.06.2015
Former [2016/06]AT25.02.2015
CZ25.02.2015
DK25.02.2015
EE25.02.2015
FI25.02.2015
IT25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
NL25.02.2015
PL25.02.2015
RO25.02.2015
SE25.02.2015
SK25.02.2015
CH31.03.2015
LI31.03.2015
GR26.05.2015
IS25.06.2015
Former [2016/03]AT25.02.2015
CZ25.02.2015
DK25.02.2015
EE25.02.2015
FI25.02.2015
IT25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
NL25.02.2015
PL25.02.2015
RO25.02.2015
SE25.02.2015
SK25.02.2015
GR26.05.2015
IS25.06.2015
Former [2016/01]AT25.02.2015
CZ25.02.2015
DK25.02.2015
EE25.02.2015
FI25.02.2015
LT25.02.2015
LV25.02.2015
MC25.02.2015
NL25.02.2015
PL25.02.2015
RO25.02.2015
SE25.02.2015
SK25.02.2015
GR26.05.2015
IS25.06.2015
Former [2015/50]AT25.02.2015
CZ25.02.2015
DK25.02.2015
EE25.02.2015
FI25.02.2015
LT25.02.2015
LV25.02.2015
NL25.02.2015
PL25.02.2015
RO25.02.2015
SE25.02.2015
SK25.02.2015
GR26.05.2015
IS25.06.2015
Former [2015/49]AT25.02.2015
CZ25.02.2015
DK25.02.2015
EE25.02.2015
FI25.02.2015
LT25.02.2015
LV25.02.2015
NL25.02.2015
RO25.02.2015
SE25.02.2015
SK25.02.2015
GR26.05.2015
IS25.06.2015
Former [2015/41]AT25.02.2015
FI25.02.2015
LT25.02.2015
LV25.02.2015
NL25.02.2015
SE25.02.2015
GR26.05.2015
IS25.06.2015
Former [2015/39]AT25.02.2015
FI25.02.2015
LT25.02.2015
LV25.02.2015
SE25.02.2015
GR26.05.2015
IS25.06.2015
Former [2015/38]AT25.02.2015
FI25.02.2015
LT25.02.2015
SE25.02.2015
GR26.05.2015
IS25.06.2015
Former [2015/37]FI25.02.2015
LT25.02.2015
SE25.02.2015
GR26.05.2015
Former [2015/36]FI25.02.2015
LT25.02.2015
SE25.02.2015
Former [2015/35]LT25.02.2015
Documents cited:Search[X]WO9719079  (FOSCAMA BIOMED CHIM FARMA [IT], et al) [X] 1-4,9 * pages 14-15; example 2 * * claims 1,2,4-8 *;
 [A]WO9909845  (BRISTOL MYERS SQUIBB CO [US]) [A] 1-14 * claims 1-44 ** page 1, lines 10-14 *;
 [YD]US6083505  (MILLER RICHARD L [US], et al) [YD] 1-14 * column 3, line 4 - column 7, line 21 * * claims 1-16 *;
 [Y]US2003022898  (BURKE JAMES R [US], et al) [Y] 1-14 * page 1, paragraph 2 * * page 3, paragraph 30 * * page 30; example 12 * * page 31; example 16 * * claims 1-50 *;
 [X]  - CECCARELLI S ET AL, "Imidazo[1,2-a]quinoxalin-4-amines: A novel class of nonxanthine A1-adenosine receptor antagonists", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 33, no. 12, ISSN 0223-5234, (199812), pages 943 - 955, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, XP004160900 [X] 1-4,9 * page 947; table II; compound 19 * * page 943, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/S0223-5234(99)80019-1
 [X]  - DELEUZE-MASQUEFA, CARINE ET AL, "Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY , 12(5), 1129-1139 CODEN: BMECEP; ISSN: 0968-0896, (2004), BIOORGANIC & MEDICINAL CHEMISTRY , 12(5), 1129-1139 CODEN: BMECEP; ISSN: 0968-0896, XP002440985 [X] 1-4,9 * page 1132; table 1; compound 7B * * page 1129, paragraph 1 *

DOI:   http://dx.doi.org/10.1016/j.bmc.2003.11.034
by applicantEP0109942
 US4689338
 US4806352
 US4929624
 EP0372501
 EP0378881
 WO9014837
 WO9102062
 US5011828
 EP0427347
 US5026543
 US5026546
 US5057540
 EP0471177
 EP0477508
 US5238944
 WO9318150
 WO9317712
 WO9319780
 US5266575
 US5268376
 WO9400153
 US5306492
 US5346905
 WO9421292
 US5352784
 US5360897
 EP0626169
 US5378814
 US5389640
 US5395937
 WO9517210
 WO9517211
 EP0689454
 US5482936
 US5494916
 WO9611711
 US5525612
 WO9626741
 WO9629412
 WO9630514
 EP0735898
 WO9633739
 EP0761231
 US5658731
 WO9737026
 WO9743303
 US5693522
 WO9804702
 EP0835318
 WO9818931
 WO9818930
 WO9840100
 WO9842375
 WO9842721
 US5846538
 WO9857659
 WO9858668
 US5869445
 WO9911241
 WO9924578
 WO9927105
 WO9927960
 WO9928475
 WO9929693
 US5916588
 WO9936544
 WO9952549
 WO9953310
 WO9957280
 WO9958562
 WO9962923
 US6015567
 WO0007621
 WO0022430
 WO0023105
 WO0027994
 WO0037494
 US6083505
 US6090406
 US6110929
 WO0056360
 WO0067161
 WO0108636
 US6207646
 WO0121207
 WO0121152
 US6239116
 WO0137869
 WO0152885
 US6284772
 US6299884
 WO0195935
 US6333164
 WO0202606
 US2002007173
 WO0218383
 WO0218595
 WO0226757
 WO0234771
 US6429199
 US6440992
 US6451325
 WO02079243
 WO02085905
 WO02094851
 WO03002065
 WO03011223
 WO03024480
 WO03024481
 WO03035836
 WO03043572
 WO03049762
 US6605617
 WO03068811
 US6627640
 US6630161
 WO03082272
 WO03093306
 WO03097641
 US6656938
 US6660735
 US6660747
 US6664260
 US6664264
 US6664265
 US6667312
 US6670372
 US6677347
 US6677348
 US6677349
 WO2004005473
 US6683088
 US6699703
 WO2004018455
 US6703402
 WO2004041157
 US6743920
 US6756361
 WO2004060308
 WO2004064759
 WO2004064715
 WO2004071459
 WO2004076677
 US6800624
 US6800744
 WO2004087153
 US6809203
 WO2004092360
 WO2005002619
 WO2005025614
 US2005070556
 WO2005032582
 US6888000
 US6924293
 US6924271
 US2005215517
    - "Current Status of Immunological Adjuvants", ANN. REV. IMMUNOL., (1986), vol. 4, pages 369 - 388
    - DEREK T O'HAGAN, NICHOLAS M. VALIANTE, RECENT ADVANCES IN VACCINE ADJUVANTS AND DELIVERY SYSTEMS
    - MATTSON, CHAN, SCIENCE, (2003), vol. 301, no. 1 1, pages 847 - 9
    - PODDA, "The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine", VACCINE, (2001), vol. 19, pages 2673 - 2680
    - FREY ET AL., "Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non- adjuvanted influenza vaccine in non-elderly adults", VACCINE, (2003), vol. 21, pages 4234 - 4237
    - "MF59 -- Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines", OTT ET AL., Vaccine Design: The Subunit and Adjuvant Approach, PLENUM PRESS, (1995), pages 277 - 296
    - PODDA, DEL GIUDICE, EXPERT REV VACCINES, (2003), vol. 2, pages 197 - 203
    - PODDA, VACCINE, (2001), vol. 19, pages 2673 - 2680
    - "Methods in Molecular Medicine series", O'HAGAN, Vaccine Adjuvants: Preparation Methods and Research Protocols, vol. 42
    - ALLISON, BYARS, RES IMMUNOL, (1992), vol. 143, pages 519 - 25
    - HARIHARAN ET AL., CANCER RES, (1995), vol. 55, pages 3486 - 9
    - BARR ET AL., "ISCOMs and other saponin based adjuvants", ADVANCED DRUG DELIVERY REVIEWS, (1998), vol. 32, pages 247 - 271
    - SJOLANDER ET AL., "Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines", ADVANCED DRUG DELIVERY REVIEWS, (1998), vol. 32, pages 321 - 338
    - NIIKURA ET AL., "Chimeric Recombinant Hepatitis E Virus-Like Particles as an Oral Vaccine Vehicle Presenting Foreign Epitopes", VIROLOGY, (2002), vol. 293, pages 273 - 280
    - LENZ ET AL., "Papillomarivurs-Like Particles Induce Acute Activation of Dendritic Cells", JOURNAL OF IMMUNOLOGY, (2001), pages 5246 - 5355
    - PINTO ET AL., "Cellular Immune Responses to Human Papillomavirus (HPV)-16 L Healthy Volunteers Immunized with Recombinant HPV-16 L Virus-Like Particles", JOURNAL OF INFECTIOUS DISEASES, (2003), vol. 188, pages 327 - 338
    - GERBER ET AL., "Human Papillomavirus Virus-Like Particles Are Efficient Oral Immunogens when Coadministered with Escherichia coli Heat-Labile Entertoxin Mutant R192G or CpG", JOURNAL OF VIROLOGY, (2001), vol. 75, no. 10, pages 4752 - 4760
    - GLUCK ET AL., "New Technology Platforms in the Development of Vaccines for the Future", VACCINE, (2002), vol. 20, pages B10 - B16
    - MISCHLER, METCALFE, VACCINE, (2002), vol. 20, no. 5, pages B17 - 23
    - JOHNSON ET AL., BIOORG MED CHEM LETT, (1999), vol. 9, pages 2273 - 2278
    - THOMPSON ET AL., J LEUKOC BIOL, (2005), page 78
    - MERALDI ET AL., "OM-174, a New Adjuvant with a Potential for Human Use, Induces a Protective Response with Administered with the Synthetic C-Terminal Fragment 242-310 from the circumsporozoite protein of Plasmodium berghei", VACCINE, (2003), vol. 21, pages 2485 - 2491
    - PAJAK ET AL., "The Adjuvant OM-174 induces both the migration and maturation of murine dendritic cells in vivo", VACCINE, (2003), vol. 21, pages 836 - 842
    - KANDIMALLA ET AL., "Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles", NUCLEIC ACIDS RESEARCH, (2003), vol. 31, no. 9, pages 2393 - 2400
    - KRIEG, "CpG motifs: the active ingredient in bacterial extracts?", NATURE MEDICINE, (2003), vol. 9, no. 7, pages 831 - 835
    - MCCLUSKIE ET AL., "Parenteral and mucosal prime-boost immunization strategies in mice with hepatitis B surface antigen and CpG DNA", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, (2002), vol. 32, pages 179 - 185
    - KANDIMALLA ET AL., "Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic CpG DNAs", BIOCHEMICAL SOCIETY TRANSACTIONS, (2003), vol. 31, pages 654 - 658
    - BLACKWELL ET AL., "CpG-A-Induced Monocyte IFN-gamma-Inducible Protein-10 Production is Regulated by Plasmacytoid Dendritic Cell Derived IFN-alpha", J. IMMUNOL., (2003), vol. 170, no. 8, pages 4061 - 4068
    - KRIEG, "From A to Z on CpG", TRENDS IN IMMUNOLOGY, (2002), vol. 23, no. 2, pages 64 - 65
    - KANDIMALLA ET AL., "Secondary structures in CpG oligonucleotides affect immunostimulatory activity", BBRC, (2003), vol. 306, pages 948 - 953
    - KANDIMALLA ET AL., "Toll-like receptor 9: modulation of recognition and cytokine induction by novel synthetic GpG DNAs", BIOCHEMICAL SOCIETY TRANSACTIONS, (2003), vol. 31, pages 664 - 658
    - BHAGAT ET AL., "CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents", BBRC, (2003), vol. 300, pages 853 - 861
    - BEIGNON ET AL., "The LTR72 Mutant of Heat-Labile Enterotoxin of Escherichia coli Enhances the Ability of Peptide Antigens to Elicit CD4+ T Cells and Secrete Gamma Interferon after Coapplication onto Bare Skin", INFECTION AND IMMUNITY, (2002), vol. 70, no. 6, pages 3012 - 3019
    - PIZZA ET AL., "Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants", VACCINE, (2001), vol. 19, pages 2534 - 2541
    - PIZZA ET AL., "LTK63 and LTR72, two mucosal adjuvants ready for clinical trials", INT. J. MED. MICROBIOL, (2000), vol. 290, no. 4-5, pages 455 - 461
    - SCHARTON-KERSTEN ET AL., "Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits and Unrelated Adjuvants", INFECTION AND IMMUNITY, (2000), vol. 68, no. 9, pages 5306 - 5313
    - RYAN ET AL., "Mutants of Escherichia coli Heat-Labile Toxin Act as Effective Mucosal Adjuvants for Nasal Delivery of an Acellular Pertussis Vaccine: Differential Effects of the Nontoxic AB Complex and Enzyme Activity on Thl and Th2 Cells", INFECTION AND IMMUNITY, (1999), vol. 67, no. 12, pages 6270 - 6280
    - PARTIDOS ET AL., "Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides", IMMUNOL. LETT., (1999), vol. 67, no. 3, pages 209 - 216
    - PEPPOLONI ET AL., "Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines", VACCINES, (2003), vol. 2, no. 2, pages 285 - 293
    - PINE ET AL., "Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63", J. CONTROL RELEASE, (2002), vol. 85, no. 1-3, pages 263 - 270
    - DOMENIGHINI ET AL., MOL. MICROBIOL, (1995), vol. 15, no. 6, pages 1165 - 1167
    - SINGH ET AL., J. CONT. RELE., (2001), vol. 70, pages 267 - 276
    - ANDRIANOV ET AL., "Preparation of hydrogel microspheres by coacervation of aqueous polyphophazene solutions", BIOMATERIALS, (1998), vol. 19, no. 1-3, pages 109 - 115
    - PAYNE ET AL., "Protein Release from Polyphosphazene Matrices", ADV. DRUG. DELIVERY REVIEW, (1998), vol. 31, no. 3, pages 185 - 196
    - STANLEY, "Imiquimod and the imidazoquinolines: mechanism of action and therapeutic potential", CLIN EXP DERMATOL, (2002), vol. 27, no. 7, pages 571 - 577
    - JONES, "Resiquimod 3M", CURR OPIN INVESTIG DRUGS, (2003), vol. 4, no. 2, pages 214 - 218
    - WU ET AL., ANTIVIRAL RES., (2004), vol. 64, no. 2, pages 79 - 83
    - VASILAKOS ET AL., CELL IMMUNOL., (2000), vol. 204, no. 1, pages 64 - 74
    - SIGNORELLI, HADDEN, INT IMMUNOPHARMACOL, (2003), vol. 3, no. 8, pages 1177 - 86
    - COOPER, PHARM BIOTECHNOL, (1995), vol. 6, pages 559 - 80
    - SABROE ET AL., JL, (2003), pages 1630 - 5
    - WONG ET AL., J CLIN PHARMACOL, (2003), vol. 43, no. 7, pages 735 - 42
    - EVANS ET AL., EXPERT REV VACCINES, (2003), vol. 2, pages 219 - 229
    - THOMPSON ET AL., METHODS IN MOLECULAR MEDICINE, (2003), vol. 94, pages 255 - 266
    - DALE, VACCINE, (1999), vol. 17, pages 193 - 200
    - DALE, VACCINE, vol. 14, no. 10, pages 944 - 948
    - INFECT IMMUN., (20010506), vol. 9, no. 5, pages 3510 - 3515
    - ZHU ET AL., VACCINE, (2004), vol. 22, pages 660 - 669
    - PRICE ET AL., INFECTION AND IMMUNITY, (2004), vol. 71, no. 1, pages 277 - 283
    - PLANTE ET AL., J INFECTIOUS DISEASE, (2000), vol. 182, pages 848 - 855
    - INFECT LMMUN, (20030107), vol. 1, no. 11, pages 374 - 383
    - INFECT IMMUN., (199910), vol. 67, no. 10, page 5395
    - INFECT IMMUN., (199711), vol. 65, no. 11, pages 4476 - 4482
    - INFECT IMMUN., (200410), vol. 72, no. 10, page 6148
    - PROC NATL ACAD SCI US A, (20040824), vol. 101, no. 34, page 12652
    - INFECT IMMUN., (200407), vol. 72, no. 7, page 3829
    - BIOCHIM BIOPHYS ACTA, (20041101), vol. 1702, no. 2, page 145
    - J AUTOIMMUN., (198906), vol. 2, page 81
    - INFECT LMMUN., (200310), vol. 71, no. 10, pages 5498 - 504
    - INFECT IMMUN, (200105), vol. 69, no. 5, pages 3323 - 3334
    - J CLIN MICROBIOL, (199912), vol. 37, no. 12, page 3997
    - CAN JBIOCHEM CELL BIOL., (198405), vol. 62, no. 5, pages 270 - 5
    - HSU ET AL., CLIN LIVER DIS, (1999), vol. 3, pages 901 - 915
    - HOUGHTON ET AL., HEPATOLOGY, (1991), vol. 14, page 381
    - MOINGEON P, "Cancer vaccines", VACCINE, (2001), vol. 19, pages 1305 - 1326
    - ROSENBERG SA, "Progress in human tumor immunology and immunotherapy", NATURE, (2001), vol. 411, pages 380 - 384
    - DERMINE, S. ET AL., "Cancer Vaccines and Immunotherapy", BRITISH MEDICAL BULLETIN, (2002), vol. 62, pages 149 - 162
    - ESPINOZA-DELGADO I., "Cancer Vaccines", THE ONCOLOGIST, (2002), vol. 7, no. 3, pages 20 - 33
    - DAVIS, I.D. ET AL., "Rational approaches to human cancer immunotherapy", JOURNAL OF LEUKOCYTE BIOLOGY, (2003), vol. 23, pages 3 - 29
    - VAN DEN EYNDE B ET AL., "New tumor antigens recognized by T cells", CURR. OPIN. IMMUNOL., (1995), vol. 7, pages 674 - 81
    - ROSENBERG SA, "Cancer vaccines based on the identification of genes encoding cancer regression antigens", IMMUNOL. TODAY, (1997), vol. 18, pages 175 - 82
    - OFFRINGA R ET AL., "Design and evaluation of antigen-specific vaccination strategies against cancer", CURRENT OPIN. IMMUNOL., (2000), vol. 2, pages 576 - 582
    - ROSENBERG SA, "A new era for cancer immunotherapy based on the genes that encode cancer antigens", IMMUNITY, (1999), vol. 10, pages 281 - 7
    - SAHIN U ET AL., "Serological identification of human tumor antigens", CURR. OPIN. IMMUNOL., (1997), vol. 9, pages 709 - 16
    - OLD LJ ET AL., "New paths in human cancer serology", J. EXP. MED., (1998), vol. 187, pages 1163 - 7
    - CHAUX P ET AL., "Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes", J. EXP. MED., (1999), vol. 189, pages 767 - 78
    - GOLD P ET AL., "Specific carcinoembryonic antigens of the human digestive system", J. EXP. MED., (1965), vol. 122, pages 467 - 8
    - LIVINGSTON PO ET AL., "Carbohydrate vaccines that induce antibodies against cancer: Rationale", CANCER IMMUNOL. IMMUNOTHER., (1997), vol. 45, pages 1 - 6
    - LIVINGSTON PO ET AL., "Carbohydrate vaccines that induce antibodies against cancer: Previous experience and future plans", CANCER IMMUNOL. IMMUNOTHER., (1997), vol. 45, pages 10 - 9
    - TAYLOR-PAPADIMITRIOU J, "Biology, biochemistry and immunology of carcinoma- associated mucins", IMMUNOL. TODAY, (1997), vol. 18, pages 105 - 7
    - ZHAO X-J ET AL., "GD2 oligosaccharide: target for cytotoxic T lymphocytes", J. EXP. MED., (1995), vol. 182, pages 67 - 74
    - THEOBALD M ET AL., "Targeting p53 as a general tumor antigen", PROC. NATL. ACAD. SCI. USA, (1995), vol. 92, pages 11993 - 7
    - GAUDERNACK G, "T cell responses against mutant ras: a basis for novel cancer vaccines", IMMUNOTECHNOLOGY, (1996), vol. 2, pages 3 - 9
    - PRESCOTT, Methods in Cell Biology, ACADEMIC PRESS, (1976), vol. XIV, page 33
    - LEE, DIFFUSION-CONTROLLED MATRIX SYSTEMS, pages 155 - 198
    - RON, LANGER, ERODIBLE SYSTEMS, pages 199 - 224
    - TETTELIN ET AL., SCIENCE, (2000), vol. 287, pages 1809 - 1815
    - PIZZA ET AL., SCIENCE, (2000), vol. 287, pages 1816 - 1820
    - BJUNE ET AL., LANCET, (1991), vol. 338
    - FUSKASAWA ET AL., VACCINE, (1999), vol. 17, pages 2951 - 2958
    - ROSENQIST ET AL., DEV. BIOL. STRAND, (1998), vol. 92, pages 323 - 333
    - CONSTANTINO ET AL., VACCINE, (1992), vol. 10, pages 691 - 698
    - CONSTANTINO ET AL., VACCINE, (1999), vol. 17, pages 1251 - 1263
    - WATSON, PEDIATR INFECT DIS J, (2000), vol. 19, pages 331 - 332
    - RUBIN, PEDIATR CLIN NORTH AM, (2000), vol. 47, pages 269 - 285
    - JEDRZEJAS, MICROBIOL MOL BIOL REV, (2001), vol. 65, pages 187 - 207
    - KALMAN ET AL., NATURE GENETICS, (1999), vol. 21, pages 385 - 389
    - READ ET AL., NUCLEIC ACIDS RES, (2000), vol. 28, pages 1397 - 406
    - SHIRAI ET AL., J. INFECT. DIS, (2000), vol. 181, no. 3, pages S524 - S527
    - BELL, PEDIATR INFECT DIS J, (2000), vol. 19, pages 1187 - 1188
    - IWARSON, APMIS, (1995), vol. 103, pages 321 - 326
    - GERLICH ET AL., VACCINE, (1990), vol. 8, pages 63 - 68,79-80
    - GASTOFSSON ET AL., N. ENGL. J. MED., (1996), vol. 334, pages 349 - 355
    - RAPPUOLI ET AL., TIBTECH, (1991), vol. 9, pages 232 - 238
    - DEL GUIDICE ET AL., MOLECULAR ASPECTS OF MEDICINE, (1998), vol. 19, pages 1 - 70
    - ROSS ET AL., VACCINE, (2001), vol. 19, pages 135 - 142
    - SUTTER ET AL., PEDIATR CLIN NORTH AM, (2000), vol. 47, pages 287 - 308
    - ZIMMERMAN, SPANN, AM FAN PHYSICIAN, (1999), vol. 59, pages 113 - 118,125-126
    - DREENSEN, VACCINE, (1997), vol. 15, pages 2 - 6
    - MMWR MORB MORTAL WKLY REP, (19980116), vol. 47, no. 1, page 12,9
    - MCMICHAEL, VACCINE, (2000), vol. L9, no. 1, pages 101 - 107
    - SCHUCHAT, LANCER, (1999), vol. 353, no. 9146, pages 51 - 6
    - DALE, INFECT DISCLIN NORTH AM, (1999), vol. 13, pages 227 - 43
    - FERRETTI ET AL., PNAS USA, (2001), vol. 98, pages 4658 - 4663
    - KURODA ET AL., LANCET, (2001), vol. 357, no. 9264, pages 1225 - 1240,1218-1219
    - RAMSAY ET AL., LANCET, (2001), vol. 357, no. 9251, pages 195 - 196
    - LINDBERG, VACCINE, (1999), vol. 17, no. 2, pages 28 - 36
    - BUTTERY, MOXON, J R COIL PHYSICIANS LONG, (2000), vol. 34, pages 163 - 168
    - AHMAD, CHAPNICK, INFECT DIS CLIN NORTH AM, (1999), vol. 13, pages 113 - 133
    - GOLDBLATT, J. MED. MICROBIOL., (1998), vol. 47, pages 663 - 567
    - CRUSE ET AL, Conjugate Vaccines, vol. 10, pages 48 - 114
    - MACKAY, B., POCKET PETS, ANIMAL ISSUES, (2001), vol. 32, no. 1
    - T. HIGUCHI, V. STELLA, Pro-drugs as Novel Delivery Systems, A.C.S. SYMPOSIUM SERIES, vol. 14
    - STEPHANIE PARRA, "Imidazo[1,2-a]quinoxalines: synthesis and cyclic nucleotide phosphodiesterase inhibitory activity.", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, (2001), vol. 36, pages 255 - 264
    - CHUN-HE LIU, "Design, synthesis and biological evaluation of novel 4-alkylamino-1-hydroxymethylimidazo[1,2-a]quinoxalines as adenosine Al receptor antagonists.", BIOORGANIC AND MEDICINAL CHEMISTRY, (2004), vol. 12, pages 4701 - 4707
    - CARINE DELEUZE-MASQUEFA, "Design and synthesis of novel imidazo[1,2-a]quinoxaolines as PDE4 inhibitors.", BIOORGANIC AND MEDICINAL CHEMISTRY, (2004), vol. 12, pages 1129 - 1139
    - N. SATO., "Product class 14: pyrazines.", SCIENCE OF SYNTHESIS, (2004), vol. 16, pages 751 - 844
    - JIRO ADACHI, NOBUHIRO SATO, "Pyrazines. 1. Syntheses of 2,3-dihydroxypyrazines and their derivatives.", JOURNAL OF ORGANIC CHEMISTRY, (1972), vol. 37, no. 2, pages 221 - 5
    - GEO KARMAS., PAUL E, SPOERRI, "Displacements and nuclear substitutions on hydroxypyrazines.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, (1956), vol. 78, pages 4071 - 7
    - JIRO TSUJI, Palladium Reagents and Catalysts: Innovations in Organic Chemistry, JOHN WILEY & SONS LTD.
    - CARINE DELEUZE-MASQUEFA, GREGORI GEREBTZOFF, GUY SUBRA, JEAN-ROCH FABREGUETTES, ANNABEL OVENS, MAELLE CARRAZ, MARIE-PAULE STRUB, J, "Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY, (2004), vol. 12, no. 5, pages 1129 - 1139
    - CHUN-HE LIU, BO WANG, WEI-ZHANG LI, LIU-HONG YUN, YING LIU, RUI-BING SU, JIN LI, HE LIU, "Design, synthesis, and biological evaluation of novel 4-alkylamino-1-hydroxymethylimidazo[1,2-a]quinoxalines as adenosine A1 receptor antagonist", BIOORGANIC & MEDICINAL CHEMISTRY, (2004), vol. 12, no. 17, pages 4701 - 4707
    - POPE ET AL., CELLULAR IMMUNOLOGY, (1995), vol. 162, pages 333 - 339
    - RAZ ET AL., PROC. NATL. ACAD. SCI. USA, (1994), vol. 91, pages 9519 - 9523
    - PHARM RES., (200412), vol. 21, no. 12, pages 2148 - 52
 US20000581772
 GB20010005640
 US20030405495
 US20030748071
 US20040762873
 US20040814480
 WO2005US22769
 WO2005US22520
 WO2005US32721
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.